Clinical Trials

27 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03641456 2023-06-18

VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

50 enrolled

Neoplasms, Plasma Cell

NCT00464178 2022-07-20

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

7 enrolled 5 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

51 enrolled

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT02424851 2022-01-27

OPTIMAL

31 enrolled 13 charts

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

NCT00792142 2021-08-19

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

45 enrolled 8 charts

Multiple Myeloma, Neurotoxicity Syndromes, Neoplasms, Plasma Cell

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

637 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT00469209 2020-09-24

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

Phase 1/2 Completed

60 enrolled 7 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00084747 2020-08-17

Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

Phase 1/2 Completed

30 enrolled 7 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00985907 2020-06-17

DMV

Phase 1/2 Terminated

13 enrolled 8 charts

Multiple Myeloma, Patient Participation, Neoplasms, Plasma Cell

NCT01497093 2020-04-07

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

34 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01023308 2020-03-17

PANORAMA-1

767 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01438177 2020-02-24

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

11 enrolled 9 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00568880 2020-02-07

Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

25 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01647165 2019-12-12

Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00948922 2019-09-18

Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

124 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02188537 2019-06-26

Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma

34 enrolled

Neoplasms, Plasma Cell

NCT01164709 2019-05-15

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

DermatologicLymphoidOther hematologic neoplasmPlasma cell

18 enrolled

Congenital Abnormalities, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Follicular, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell

NCT01191060 2019-04-18

IFM/DFCI2009

700 enrolled

Disease Progression, Neoplasms, Plasma Cell

NCT01440582 2019-03-04

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

77 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01554852 2018-06-11

Myeloma XI

Phase 3 Unknown

4,420 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01315873 2018-02-07

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

24 enrolled 3 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00744354 2018-01-18

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Terminated

32 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01332617 2017-12-29

Phase II Study of Simvastatin for Relapsed/Refractory Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00473590 2017-06-14

AMBER

102 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00523848 2017-02-23

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

46 enrolled 8 charts

Phase EARLY_PHASE1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01171092 2017-01-11

A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma

21 enrolled

LymphoidPlasma cell

Lymphoma, Neoplasms, Plasma Cell

NCT00504101 2016-12-15

Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma

Phase 1 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00458822 2016-08-10

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

40 enrolled 5 charts

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00983346 2016-07-11

Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients

17 enrolled 5 charts

Smoldering Multiple Myeloma, Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Unknown

98 enrolled

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00111748 2015-10-06

UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients

180 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00814541 2014-12-31

PAD. ICORG 05-01, V11

53 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00389701 2014-01-10

Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment

30 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02027220 2014-01-06

Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma

60 enrolled

Neoplasms, Plasma Cell

NCT00742404 2013-12-18

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

35 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00288028 2013-11-19

Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant

15 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00317811 2013-11-06

Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma

35 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00316940 2013-09-20

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

36 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00258245 2013-04-29

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

5 enrolled